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Recombinant adeno-associated viruses (AAVs) are popular in vivo gene transfer vehicles. However, vector doses needed to achieve
therapeutic effect are high and some target tissues in the central nervous system remain difﬁcult to transduce. Gene therapy trials
using AAV for the treatment of neurological disorders have seldom led to demonstrated clinical efﬁcacy. Important contributing
factors are low transduction rates and inefﬁcient distribution of the vector. To overcome these hurdles, a variety of capsid
engineering methods have been utilized to generate capsids with improved transduction properties. Here we describe an alternative
approach to capsid engineering, which draws on the natural evolution of the virus and aims to yield capsids that are better suited
to infect human tissues. We generated an AAV capsid to include amino acids that are conserved among natural AAV2 isolates and
tested its biodistribution properties in mice and rats. Intriguingly, this novel variant, AAV-TT, demonstrates strong neurotropism
in rodents and displays signiﬁcantly improved distribution throughout the central nervous system as compared to AAV2.
Additionally, sub-retinal injections in mice revealed markedly enhanced transduction of photoreceptor cells when compared to
AAV2. Importantly, AAV-TT exceeds the distribution abilities of benchmark neurotropic serotypes AAV9 and AAVrh10 in the
central nervous system of mice, and is the only virus, when administered at low dose, that is able to correct the neurological
phenotype in a mouse model of mucopolysaccharidosis IIIC, a transmembrane enzyme lysosomal storage disease, which requires
delivery to every cell for biochemical correction. These data represent unprecedented correction of a lysosomal transmembrane
enzyme deﬁciency in mice and suggest that AAV-TT-based gene therapies may be suitable for treatment of human neurological
diseases such as mucopolysaccharidosis IIIC, which is characterized by global neuropathology.
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Introduction
Recent clinical trials have demonstrated safety and efﬁcacy
of adeno-associated virus (AAV)-mediated gene therapies
targeting the eye, muscle and liver (Nathwani et al.,
2014; Bainbridge et al., 2015; Russell et al., 2017; Sparks
Therapeutics, 2017). However, despite recent unparalleled
results in an AAV gene therapy trial for spinal muscular
atrophy (Mendell et al., 2017), other AAV gene therapies
directed at the brain of patients with rare neurological dis-
eases have shown only limited efﬁcacy (Worgall et al.,
2008; Tardieu et al., 2014, 2017). One of the main difﬁ-
culties associated with gene therapy for CNS diseases is the
inefﬁcient AAV distribution to neurons from injection sites
in patients. To overcome this hurdle, various strategies
have been used to identify or generate more suitable AAV
capsids for CNS transduction. These include the discovery
of new AAV serotypes in humans and non-human primates
and the thorough characterization of their brain tropism
(Gao et al., 2002, 2004; Cearley and Wolfe, 2006; Foust
et al., 2009; Bevan et al., 2011). Concurrently, diverse
capsid engineering strategies emerged as approaches to
direct the AAV vectors to deﬁned cell types (Mu¨ller
et al., 2003; Chen et al., 2009; Adachi et al., 2014).
AAV capsids can be improved through rational design, dir-
ected evolution techniques and in vivo selection in mouse
or humanized mouse models (Asokan et al., 2010; Shen
et al., 2013; Kotterman and Schaffer, 2014; Lisowski
et al., 2014; Tervo et al., 2016; Kanaan et al., 2017).
Recently, a novel engineering approach based on in silico
reconstruction of ancestral viruses has yielded a promising
vector for gene therapy of diseases that affect liver, muscle
or retina (Zinn et al., 2015). Here we report an alternative
evolutionary approach to AAV capsid design based on the
introduction of amino acids conserved in AAV2 variants
that are currently circulating in the human population
(Chen et al., 2005).
This yields a potent neurotropic vector, which may be
ideally suited to treat human neurological diseases such
as mucopolysaccharidosis type IIIC (MPSIIIC). This disease
is caused by mutations in the heparan sulphate acetyl-CoA:
-glucosaminide N-acetyltransferase (HGSNAT) gene, re-
sulting in a deﬁciency in the lysosomal enzyme HGSNAT
(EC 2.3.1.78). Deﬁciency of HGSNAT causes progressive
accumulation of undegraded heparan sulphate (HS) in all
cells of the body (Ruijter et al., 2008). Patients with
MPSIIIC have mild visceral manifestations; however,
neurological symptoms are severe, characterized by behav-
ioural problems, cognitive decline and, eventually, dementia
and death in early adulthood (Ruijter et al., 2008; Valstar
et al., 2008). Neuroinﬂammation and storage of secondary
substrates contribute to the pathology of the disease
(Archer et al., 2014). The HGSNAT protein is a transmem-
brane lysosomal N-acetyltransferase, and thus enzyme re-
placement therapy approaches relying on cellular uptake of
exogenous enzyme by mannose 6 phosphate receptors that
are effective in other lysosomal diseases, cannot be used in
this setting. Alternatives, including haematopoietic stem cell
transplantation, or gene modiﬁcation of these cells, also
rely on cross-correction and therefore will also most
likely prove ineffectual (Durand et al., 2010). The majority
of the clinical phenotype is neurological in MPSIIIC, with
global neuropathology (Martins et al., 2015), therefore
direct transgene delivery to the brain using AAV ensuring
distribution to the largest number of cells possible may
prove beneﬁcial. This approach has been used in both
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preclinical studies and clinical trials for the cross-correct-
able diseases MPSIIIA (Tardieu et al., 2014; Winner et al.,
2016) and MPSIIIB (Ellinwood et al., 2011; Tardieu et al.,
2017) caused by deﬁciencies of soluble secreted enzymes
using serotypes rhesus 10 (rh10) and 5, respectively, but
even in this case clinical efﬁcacy has been limited.
Improved vector distribution in the brain is paramount to
overcome these issues, particularly in the case of non-se-
creted neurological proteins, such as the one deﬁcient in
MPSIIIC. Here we present data demonstrating that an al-
ternative approach to capsid engineering, drawing on the
natural evolution of the virus, yields a potent neurotropic
vector that is more effectively distributed within the brain
than the benchmark vectors AAV9 and AAVrh10, and dis-
plays an improved ability to correct the neurological
phenotype in MPSIIIC mice. The utilization of AAV-TT
paves the way for more effective clinical correction of
neurological diseases such as MPSIIIC.
Material and methods
AAV-TT model generation
The AAV2-TT monomer model was generated with Swiss-
model (https://swissmodel.expasy.org) (Biasini et al., 2014)
using the AAV2 crystal structure (RSCB PDB ID no. 1LP3)
supplied as a template and the AAV-TT sequence. The
AAV-TT VP3 60-mer capsid coordinates were generated
by icosahedral matrix multiplication using the Oligomer
Generator subroutine available on the VIPERdb online
server (http://viperdb.scripps.edu) (Carrillo-Tripp et al.,
2009) and visualized by the program Pymol (The
PyMOL Molecular Graphics System, Version 1.8
Schro¨dinger, LLC.).
Animals
Outbred CD1 mice were time mated to produce neonatal
animals. Female Sprague Dawley rats (225–250 g) were
purchased from Charles River and were housed with free
access to food and water under a 12 hour light/dark cycle
in a temperature-controlled room. All experimental proced-
ures were approved by the Ethical Committee for Use of
Laboratory Animals in the Lund-Malmou¨ region.
Mice used for ocular injections were female C57Bl/6J
mice and were housed at University College London facil-
ities. All animal experiments were conducted according to
the ARVO Statement for the Use of Animals for Vision and
Ophthalmic Research.
The MPSIIIC mouse model with targeted disruption of
the Hgsnat gene was generated previously (Martins et al.,
2015). MPSIIIC and wild-type mice were maintained
at 21  1C, with a constant humidity of 45–65%, on a
12 h light/dark cycle with ad libitum access to food
and water. These studies were approved by the
Ethics Committee of the University of Manchester. All
studies performed on mice were approved by the UK
Home Ofﬁce for the conduct of regulated procedures
under license according to the Animals (Scientiﬁc
Procedures) Act 1986.
Recombinant AAV vector production
The AAV-CAG coHGSNAT transgene plasmid was con-
structed by replacing the GFP coding sequence in the
pTRUF-11 plasmid (ATCC, MBA-331) with a human
codon-optimized HGSNAT cDNA (including a Kozak se-
quence) into the SbfI and SphI sites.
Recombinant AAV was produced, puriﬁed and titred
using standard procedures (Supplementary material). The
vectors were titre-matched before injection.
Intracranial injections
Intracranial injections in neonatal mice were carried out as
previously described (Kim et al., 2013). Neonatal CD1
mice were prepared for injection by cryoanaesthesia at
Day 1 post-gestation (P1) and 5  1010 vector genomes
(vg) were injected via intracerebroventricular injection in
a volume of 5 ml per brain using a 33-gauge needle
(Hamilton). The experimental groups existed of equal
mixes of male and female animals.
Adult female wild-type rats were injected in the substan-
tia nigra or in the striatum at a dose of 3.5  109 vg per
injection. Rats were anaesthetized with fentanyl-dormitor
(Apoteksbolaget) and placed in the stereotactic frame
with the tooth bar individually adjusted for ﬂat skull
(bregma-lambda; tooth bar: 3 to 4mm). A hole was
drilled through the skull and the viral vectors were infused
unilaterally into the brain. Injections were performed using
a pulled glass capillary (60–80 mm internal diameter and
120–160 mm outer diameter) attached to a 25 ml Hamilton
syringe connected to an automated infusion pump system.
Infusions into the striatum used 3 ml of viral vector prepar-
ations at the following coordinates relative to the bregma:
antero-posterior (AP) = + 0.4; medio-lateral (ML) = 3.5;
dorso-ventral (DV) = 5.0/4.0, with an infusion rate of
0.4 ml/min. Infusion into the ventral midbrain used 3 ml of
viral vector at AP = 5.3; ML = 1.7; DV = 7.2, with
an infusion rate of 0.2ml/min. The capillary was left in
position for 2min before retraction.
Eight-week-old female MPSIIIC and wild-type mice
were anaesthetized and placed in a stereotactic frame.
The stereotactic coordinates used were: striatal, located
2mm lateral and 3mm deep to bregma. Using 26-gauge
Hamilton syringe, 2.6  109 vg/hemisphere were delivered
into each striatum at a rate of 0.5 ml/min (3 ml/hemisphere).
Sham treated mice received either phosphate-buffered
saline (PBS) or AAV-GFP (3 ml/hemisphere). The needle
was left in place for 5min after each infusion before
retraction.
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Intraocular injections
Intraocular injections were performed under general anaes-
thesia using an operating microscope (Supplementary
material). Six-week-old female mice were injected with viral
vectors at a dose of 2  109 vg per eye, in a volume of 2ml
per eye, and each mouse received an injection of AAV-TT in
one eye and an injection of AAV2 in the contralateral eye.
Tissue preparation
Mice that received vector as neonates were sacriﬁced at 28
days post-injection by terminal isoﬂurane anaesthesia fol-
lowed by exsanguination perfusion with PBS. The brains
were removed and ﬁxed for 48h at 4C in 4% paraformal-
dehyde (PFA) and then transferred to 30% sucrose for cryo-
protection. Brains were sectioned at 20C using a cryostat
microtome to 40 mm thickness. Sections were stored in anti-
freeze buffer (50mM sodium azide, pH 7.4 containing 25%
glycerol and 30% ethylene glycol) at 4C until use.
Adult rats were sacriﬁced 28 days post-injection by
sodium pentobarbital overdose (Apoteksbolaget) and trans-
cardially perfused with 150ml PBS followed by 250ml of
ice-cold 4% PFA in 0.1 M phosphate buffer (pH 7.4). The
brains were removed and post-ﬁxed for 2 h in ice-cold PFA
before storing in 25% buffered sucrose. Brains were cut
into coronal sections to 35 mm thickness using a sliding
microtome (HM 450, Thermo Scientiﬁc). Sections were
stored in anti-freeze solution (0.5 M sodium phosphate
buffer, 30% glycerol and 30% ethylene glycol) at 20C
until use.
Adult mice were sacriﬁced 6 weeks after intra-ocular in-
jections. Tissues were ﬁxed in 4% PFA for 1 h and then
embedded in O.C.T. medium (R.A. Lamb) and frozen in
pre-cooled isopentane. Specimens were stored at 20C
and 18 mm thick sections were cut using a Bright cryostat.
Slides were stored at 20C. Sections were air dried for
10min before immunostaining.
MPSIIIC and wild-type adult mice were anaesthetized and
transcardially perfused with 37C PBS to remove blood
from organs. Samples of liver, lung, kidneys and spleen
tissue and one hemisphere of brain were frozen at 80 C.
The other brain hemisphere was ﬁxed in 4% PFA for 24h
then treated with 30% sucrose 2mmol/l MgCl2/PBS for 48h
before freezing at 80 C. For HGSNAT assays, brain tissue
was dissected into precise hemicoronal ﬁfths (R1–R5). The
injection site was in section R2 (rostral to caudal) close to
the border of R2/R3. For HS quantiﬁcation, vector copy
number determination and thin-layer chromatography, a
full hemisphere was used. For HGSNAT and HS assays,
samples were homogenized and sonicated in homogenization
buffer (0.5mol/l NaCl, 0.02mol/l Tris pH 7–7.5), then cen-
trifuged at 2200g for 15min at 4C, and the supernatant
was collected. Protein concentration was determined using
Pierce BCA assay kit (Fisher Scientiﬁc). All brain sections
were cut from O.C.T. embedded tissues using a freezing
microtome.
Immunohistochemical staining
Immunohistochemical staining of neonatal mouse brain sec-
tions to detect GFP was performed as previously described
(Rahim et al., 2012) using the following antibodies: anti-GFP
(1:4000, ab290, Abcam), biotinylated secondary antibody
(1:1000, BA-1000, Vector Laboratories) (Supplementary
material). Representative images were captured using a live
video camera (Nikon, DS-Fil) mounted onto a Nikon Eclipse
E600 microscope.
For immunohistochemical analysis in adult rat brains, a
standard free-ﬂoating protocol was used with an anti-GFP
primary antibody (1:20 000, ab13970, Abcam). Biotinylated
secondary antibody (1:250, BA-9010, Vector Laboratories)
was used for DAB immunohistochemistry and ampliﬁed by
Vector Labs ABC kit (Supplementary material). Images were
captured using an Olympus BX53 microscope and analysed
using cellSens Dimension v. 1.11 software.
For Isolectin B4 (ILB4) staining in adult mouse brains, cor-
onal sections (30mm) were stained as previously described
(Wilkinson et al., 2012).
Quantitative analysis of
immunohistochemical staining
Levels of GFP immunohistochemical staining were mea-
sured by quantitative thresholding image analysis as previ-
ously described (Rahim et al., 2012). Data were separately
plotted graphically as the mean percentage area of immu-
noreactivity per ﬁeld [ standard error of the mean
(SEM)].
Immunofluorescence staining and
confocal microscopy
For immunoﬂuorescence analysis of neonatal mouse brain
sections, the following primary antibodies were used: anti-
GFP (1:1000, ab13970, Abcam), anti-calbindin (1:20000,
CB38, Swant), anti-TH; (1:500; AB152, Millipore), anti-
GFP (1:4000, ab290, Abcam), anti-ChAT (1:100, AB144P,
Millipore), anti-S100b (1:500, ab52642, Abcam). For im-
munoﬂuorescence, Alexa-conjugated secondary antibodies
were used. After washing in TBS, sections were counter-
stained with DAPI, mounted and coverslipped with
Fluoromount G (SouthernBiotech). Sections were visualized
with a laser scanning confocal microscope (Nikon, Eclipse
Ti-E Inverted, A1R-Si confocal) and images were processed
using NIS Elements and Photoshop software.
Eye sections were counterstained with DAPI using a 5mg/ml
solution in Tris-buffered saline (TBS) for 15min and cover-
slipped using Dako mounting medium. Microscopy of speci-
mens was performed using an upright confocal laser scanning
microscope (Leica TCS SPE DM5500 Q, Leica Microsystems)
and the manufacturer’s software (Leica LAS AF, Version
2.4.1). All images presented are confocal z-projections
through 18mm sections with DAPI in blue and eGFP in
green.
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For immunoﬂuorescence staining of 30 mm brain sections
from adult wild-type and MPSIIIC mice, the following pri-
mary antibodies were used: anti-GFP (1:1000, ab13970,
Abcam), anti-NeuN (1:500, ab177487, Abcam), anti-
GFAP (1:1500, Z-0334, Dako), anti-LAMP2 (1:200,
ab13524, Abcam). Alexa-conjugated secondary antibodies
were used. Sections were mounted using ProLong Gold
Antifade medium with DAPI (Life Technologies). Images
were acquired on a 3D-Histech Pannoramic-250 micro-
scope slide-scanner using a 20 /0.30 Plan Achromat ob-
jective (Zeiss) and the DAPI, FITC and TRITC ﬁlter sets
and processed using Case Viewer software (3D-Histech).
GFP immunoﬂuorescence was visualized at 100 on a
confocal laser scanning microscope (Leica TCS SP8).
For analysis of GM2 and GM3 gangliosides, 40mm sagittal
brain sections were incubated with anti-GM2 (KM966, 1:500)
or anti-GM3 (M2590, Cosmo Bio Co., Ltd., 1:100). Alexa-
conjugated secondary antibodies and Draq5TM solution
(ThermoFisher Scientiﬁc) were used. Sections were mounted
using Vectashield medium. The images were ﬁrst analysed
at low magniﬁcation using Zeiss Slide Scanner Axio Scan.Z1
(10 /0.45) for GM2 staining and Nikon Eclipse E800 ﬂuor-
escence microscope (5 ) for GM3 staining.
For quantiﬁcation of GM2 ganglioside, images were
acquired using a LSM510 Meta Laser inverted confocal
microscope (Zeiss, 20 /0.4) or a Leica TCS SPE confocal
microscope (10 /0.3). Quantiﬁcation of immunoﬂuores-
cence was assessed by ImageJ software (National
Institutes of Health, Bethesda, MD, USA).
Quantification of NeuN/GFP
co-localization
To demonstrate that GFP was primarily located within
neurons, automated counting was performed using the ana-
lyse particles plugin in FIJI. NeuN/GFP double positive cells
were counted using FIJI in a representative 40 section for
each brain area (n = 4 individual mice/group).
HGSNATenzyme assay
HGSNAT enzyme activity was measured using 4-methylum-
belliferyl-b-D-N-glucosaminide (MU-bGlcNH2, Moscerdam)
as a substrate (Supplementary material).
Open-field behaviour
Open ﬁeld behaviour was analysed as previously described
(Langford-Smith et al., 2011; Martins et al., 2015).
Outliers were removed using the Tukey outlier method of
1.5 interquartile range (IQR).
Spontaneous alternation
Spontaneous alternation was assessed during one continu-
ous 10-min session in a Y-maze consisting of three identical
arms as previously described (O’Leary et al., 2014). All
animals fell within the minimal 33% alternation for outlier
identiﬁcation.
Indirect enzyme-linked immunosor-
bent assay detection of anti-AAV IgG
antibodies
Total IgG antibody responses against AAV capsid proteins
were measured with an enzyme-linked immunosorbent assay
(ELISA) assay, using several brain homogenate dilutions,
biotinylated goat anti-mouse IgG antibody (Vector) and
the Vectastain ABC kit (Vector) (Supplementary material).
Vector copy number determination
Analysis of vector biodistribution was performed by quan-
titative PCR (qPCR) (Supplementary material).
Analysis of brain gangliosides by thin-
layer chromatography
Brieﬂy, frozen brain tissues were homogenized in water
(10% v/w) using a FastPrep-24 MP homogenizer. Lipids
were extracted by addition of two volumes of methanol
and one volume of chloroform to one volume of the hom-
ogenate. After 10min centrifugation at 1000g the organic
phase was collected, and used to analyse gangliosides by
phase separation as previously described (Seyrantepe et al.,
2008).
Glycosaminoglycan analysis
Glycosaminoglycan chains were puriﬁed, 2-aminoacridone
(AMAC)-labelled and analysed by reversed-phase high-per-
formance liquid chromatography (RP-HPLC) as previously
described (Holley, 2018).
Statistical analysis
Statistical analysis was performed using Graphpad Prism
software. All data were analysed by either Student’s
t-tests or ANOVA and Tukey and Sidak’s post hoc test
for analysis. Where standard deviations (SDs) were
unequal, data were log transformed to achieve normal
distributions. Signiﬁcance was determined as P5 0.05. All
the test results are given as exact values, with conﬁdence
intervals in the main text.
Experimental design
The MPSIIIC mice treated showed no phenotype at treat-
ment age. The treatment groups were randomly assigned at
weaning. MPSIIIC n-numbers were based on previous
power calculations for biochemical and histological changes
as seen in the MPSIIIA mouse model (Sergijenko et al.,
2013) and behavioural changes in the MPSIIIB mouse
model (Langford-Smith et al., 2011). It was impossible to
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blind treatment groups because of the nature of the treat-
ments and the size of the experiment, with treatments stag-
gered over several months. Analysis was carried out in a
blinded fashion for biochemical, histological and behav-
ioural analyses. The nature of the analyses was such that
unconscious bias is difﬁcult to introduce in any case, as
automated quantiﬁcation methods were used for the most
part. Data exclusion: outliers were removed from open ﬁeld
behaviour using the Tukey outlier method of 1.5  IQR.
No other mice were removed from any analysis.
Results
Engineering of a novel AAV2 capsid
We substituted 14 amino acids in the AAV2 capsid gene to
create a novel vector, designated AAV-TT, based on the
conserved amino acid changes present in natural AAV2
isolates sampled from human paediatric tissues (Chen
et al., 2005). These were one amino acid change in the
VP1 unique region (VP1u), two in the VP1/VP2 common
region, and 11 in VP3 (Fig. 1A). Most notably, arginine (R)
at positions 585 and 588 was substituted to serine (S) and
threonine (T), respectively (Fig. 1A and B). These changes
have been previously shown to abolish heparan sulphate
proteoglycan (HSPG) binding (Grifman et al., 2001; Kern
et al., 2003; Opie et al., 2003). The majority of substitu-
tions in VP3 are located on the AAV2 capsid surface and
cluster around the icosahedral 3-fold axis (Fig. 1C and D).
Ribbon diagrams show that most of the substituted amino
acids within the structurally ordered VP3 region localize to
variable regions IV–VIII (Fig. 1C and E–G), which are
involved in receptor binding and determine the antigenic
properties of AAV capsids (Gurda et al., 2013; Tseng
et al., 2015). To characterize the physical properties of
the AAV-TT capsid, its stability was determined by differ-
ential scanning ﬂuorimetry (DSF). The melting temperature
of AAV-TT is 7C greater than AAV2 (Supplementary Fig.
1A and B); the melting temperature of AAV2 is consistent
with previous reports (Rayaprolu et al., 2013). A recent
publication reported that AAV capsid stability has no cor-
relation to AAV1, AAV2, or AAV5 transduction in
HEK293 cells and that the stability of the virus is deter-
mined by its pI (Bennett et al., 2017). This implies that the
increased melting temperature of AAV-TT compared to
AAV2 is based on the difference in the number of charged
residues between the two viruses.
AAVs have been shown to use different proteoglycans as
their primary receptors. AAV-TT exhibits a high sequence
homology to AAV2 and AAV3, serotypes that are both
dependent on HSPG binding for viral uptake in vitro
(Summerford and Samulski, 1998). Recombinant AAV-TT
and AAV2 were assessed for their ability to transduce vari-
ous cell lines in vitro. Not surprisingly, AAV-TT displayed
a lower transduction efﬁciency than AAV2 and the efﬁ-
ciency of transduction of AAV-TT varied signiﬁcantly
depending on the cell type transduced [effect of treatment,
F(7,13) = 15.82, P50.0001] (Supplementary Fig. 2A). The
independence of HSPG binding of AAV-TT was further
conﬁrmed in a cell-based heparin competition assay show-
ing that AAV-TT transduction efﬁciency in vitro is not af-
fected by the presence of heparin [effect of treatment 
vector type, F(5,24) = 4.047, P5 0.01] (Supplementary
Fig. 2B); this was further substantiated by a heparin
column-binding assay. Virus-like particles were assembled
from AAV5, AAV2 or AAV-TT capsid proteins and were
loaded in excess on a heparin column (Supplementary Fig.
2C). AAV2 virus-like particles bind the heparin column and
elute with increasing NaCl concentrations, AAV5 virus-like
particles ﬂow through the column without binding to
heparin and none were further eluted when high concen-
trations of NaCl were applied. AAV-TT virus-like particles
showed a similar proﬁle to AAV5 and were only de-
tected in the ﬂow-through and the wash fractions. These
data conﬁrm that AAV-TT capsids do not interact with
heparin.
AAV-TTenables widespread
transduction in neonatal and adult
rodent brains
Prompted by previous reports that high levels of HSPG
expression in the brain parenchyma limit vector spread
(Nguyen et al., 2001; Mastakov et al., 2002; Kanaan
et al., 2017), we assessed AAV-TT’s potential for an
increased ability to spread in the brain. GFP reporter
viruses were delivered via unilateral intracerebroventricular
administration [5  1010 vector genomes (vg) total] in neo-
natal mice and biodistribution was assessed using GFP
immunohistochemistry. Figure 2A–C shows that increased
transduction levels were observed with AAV-TT as com-
pared to AAV2 in the majority of brain sections analysed;
quantiﬁcation of GFP expression in the striatum highlights
the strongly enhanced transduction capacity of AAV-TT
(two-tailed Student’s t-test; t = 13.88 df = 4, P5 0.001).
Further analysis of the tissues by immunoﬂuorescence mi-
croscopy demonstrates that both glial and neuronal cells
are targeted by AAV-TT (Fig. 2D and E). The improved
in vivo transduction proﬁle was further conﬁrmed in adult
rats where intrastriatal (Fig. 3A and B) as well as nigral
injections of 3.5  109 vg (Supplementary Fig. 3A and B)
of AAV-TT result in markedly enhanced transduction
throughout the hemisphere, whereas the delivery of
AAV2 leads to transduction of a small area of cells situated
along the needle track. Delivery of AAV-TT into the stri-
atum appears to mediate transduction across the corpus
callosum into the cortex, into the intralaminar nuclei of
the thalamus, and into the substantia nigra pars compacta
(Fig. 3A). All these regions have afferents to the striatum
(Fig. 3B), suggesting that retrograde transport may be
occurring (Salegio et al., 2013).
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Figure 1 AAV-TT capsid sequence and 3D model. (A) Protein alignment of AAV-TTand AAV2 (NCBI, accession number: NC_001401.2).
VP1 is shown, with residues in yellow highlighting the amino acids that differ between the two capsids. Residues boxed in red correspond to the
amino acid belonging to the basic patch that constitutes the HSPG binding site. Black arrows indicate the start sites of the VP2 and VP3 capsid
proteins. (B) List of AAV-TT/AAV2 differing residues located in VP3 (the amino acid change at position 205 in AAV-TT is not listed as the 3D
structure of the N-terminal end of VP3 is currently unknown). The positions of these residues within VP3 variable regions (VR) are indicated.
(C) Ribbon diagram of VP3 monomer with AAV-TT/AAV2 differing residues shown as spheres and coloured according to list in B. (D) Surface
representation of the 3D structure of AAV2 VP3 with the position of the residues which differ from AAV-TT coloured as in B. The icosahedral
2-, 3-, and 5-fold axes are indicated by an oval, triangle and pentagon, respectively. (E–G) Ribbon diagrams of VP3 dimer, trimer and pentamer
with the reference monomer coloured grey and the symmetry related monomers coloured blue.
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Figure 2 Intracerebroventricular injections in neonatal mice show superior transduction ability of AAV-TT across the CNS.
5  1010 vg of GFP-expressing AAV-TT or AAV2 vectors were injected unilaterally into the lateral ventricle of neonatal mice at postnatal Day 1
(P1) (n = 3 per condition). (A) Representative images of GFP signal observed 4 weeks post-injection in the different brain areas indicated. Brain
sections derived from an untreated animal were used as negative control (NTC, non-transduced control, n = 3). (B) High magnification images of
the sections shown in A. Scale bar = 100 mm. (C) GFP signal quantified as the percentage area of immunoreactivity measured in the striatum of
the injected hemisphere. Signal was significantly higher in AAV-TT as compared to AAV2 treated animals. Unpaired Student’s t-test, two-tailed,
n = 3 per group. The data are presented as mean  SEM; ***P5 0.001. (D) Representative images of native GFP fluorescence and calbindin,
tyrosine hydroxylase (TH), choline acetyltransferase (ChAT) or S100b taken at 40 magnification show that AAV-TT has the ability to transduce
Purkinje cells, dopaminergic neurons, cholinergic neurons and astrocytes respectively. Scale bars = 50 mm. White arrows indicate the areas
magnified in E. (E) Representative images taken at 100 magnification showing GFP expression in the areas indicated by white arrows in the
corresponding panels in D. Scale bars = 20mm.
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AAV-TTefficiently transduces
photoreceptors
Given the ability of AAV-TT to target various neuronal cell
types, we investigated if this new capsid would show im-
proved transduction of photoreceptors. AAV2 has been
used to treat a number of hereditary diseases of the eye
that cause blindness, with clinical trials showing improved
visual acuity for several years post-treatment (Ripamonti
et al., 2015; Russell et al., 2017). However, this serotype
has now been eclipsed by a number of other serotypes that
have shown improved photoreceptor tropism in preclinical
animal studies (Vandenberghe and Auricchio, 2012;
Georgiadis et al., 2016). Sub-retinal injections in mice of
AAV-TT (2  109 vg) and AAV2 (2  109 vg, contralateral
eye) allowed for side-to-side comparison of both capsid
variants; confocal microscopy of transverse sections of
the eye showed that AAV-TT has a strongly improved
ability to transduce photoreceptors as compared to
AAV2. AAV-TT transduced retinal pigment epithelium at
least as well as AAV2 (Fig. 4A). Conversely, AAV-TT vec-
tors administered via intravitreal injection showed
decreased transduction abilities (Fig. 4B), in line with pre-
vious observations that HSPG binding is required for
transduction of the retina via this injection route (Boye
et al., 2016; Woodard et al., 2016).
In summary, our data show that the introduction of a
select number of speciﬁc mutations in the AAV2 capsid
results in a potent neurotropic vector that could be used
to treat diseases of the eye as well as therapeutically more
challenging neurological diseases, such as MPSIII, which
would beneﬁt by provision of more effective CNS
transduction.
AAV-TTexceeds the transduction
abilities of AAV9 and AAVrh10 in
adult mouse brains
Many AAV serotypes have previously been assessed for
their CNS transduction properties in rodents and have
shown different expression patterns in the brain (Burger
et al., 2004; Cearley and Wolfe, 2006; Klein et al., 2006,
2008; Foust et al., 2009). In preparation for preclinical
studies, intracerebral injection of GFP reporter virus of
AAV-TT was assessed against AAV serotypes AAV9 and
AAVrh10, which had shown particularly good transduction
capabilities within the CNS in these studies. For each sero-
type, relatively low but equivalent viral titres were injected
Figure 3 Intrastriatal injections in adult rats show superior transduction ability and vector spread of AAV-TT across large
areas of the CNS. GFP-expressing AAV-TT or AAV2 (both 3.5  109 vg) were injected into the striatum of adult rat brains (n = 3).
(A) Representative images of GFP signal 4 weeks post-injection in the different brain areas indicated. (B) High magnification images of the sections
shown in A. Scale bar = 100 mm.
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bilaterally into the caudate putamen of adult mouse brains
(2.6  109 vg/hemisphere) and GFP expression assessed
after 3 weeks (Fig. 5A–C). AAV-TT resulted in greater
global transduction of cells throughout the brain compared
to either AAV9 or AAVrh10; in which spread of vector
was limited to areas within the caudate putamen and thal-
amus (Fig. 5D). AAV9 gave intense staining in the areas
close to the injection site, especially around the needle track
(Fig. 5A and D) with limited distribution in other areas. In
contrast, GFP expression of AAV-TT was less intense than
AAV9 and AAVrh10 but more widely distributed in the
brain resulting in a greater number of areas transduced;
including the cingulate cortex, thalamus, amygdala, hippo-
campus, somatosensory cortex and the external capsule,
Figure 4 Sub-retinal injections in adult mice show superior transduction ability of AAV-TT throughout different layers of the
retina. GFP expressing AAV2 and AAV-TT were injected contralaterally in adult mice at a dose of 2  109 vg per eye (n = 4 per condition).
(A) Representative confocal z-projections of transverse sections of the retina taken 4 weeks after sub-retinal injections show that AAV-TT targets
a higher number of RPE and photoreceptor cells and mediates increased transgene expression as compared to AAV2. (B) AAV-TT cannot
efficiently penetrate the retina when injected via the intra-vitreal route; intra-vitreal injection of AAV2 leads to transduction of retinal ganglion
cells. GC = ganglion cell layer; INL = inner nuclear layer; ONL = outer nuclear layer; PS = photoreceptor segments; RPE = retinal pigment epi-
thelium. Scale bar = 200 mm.
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respectively (Fig. 5B and D). GFP expression was exclu-
sively seen in neurons with expression in both the soma
and processes (Fig. 5E). We could not detect GFP in
GFAP+ astrocytes or Iba1+ microglia/macrophages
(Supplementary Fig. 4A and B). The percentages of GFP/
NeuN double positive cells were similar for AAV-TT and
AAV9 serotypes in the thalamus, an area close to the in-
jection site (Fig. 5F). However, in areas further away from
the injection site such as the amygdala and somatosensory
cortex, the percentage of GFP/NeuN double positive cells
was markedly higher in AAV-TT-treated mice compared to
AAV9-treated mice (Fig. 5G and H). We subsequently com-
pared the therapeutic efﬁcacy of AAV vectors expressing
the codon optimized human HGSNAT (coHGSNAT) trans-
gene using the two best performing serotypes; AAV9 and
AAV-TT.
Relative HGSNAT activity measured in transiently trans-
fected HEK293T cells with a plasmid containing coHGSNAT
conﬁrmed that increased HGSNAT enzyme activity was de-
tected intracellularly but not in the supernatant, thereby
conﬁrming that the enzyme cannot be secreted [effect of treat-
ment, F(5,15) = 66.75, P5 0.0001] (Supplementary Fig. 5B).
AAV-TT, but not AAV9 corrects
pathological behaviour in MPSIIIC
mice
Four months after bilateral intracranial injections (2.6  109
vg/hemisphere) of coHGSNAT expressing AAV9 and AAV-
TT vectors into MPSIIIC mice, we measured behavioural
outcomes; biochemical and histological outcomes were mea-
sured 6 months post-treatment (Fig. 6A–C).
MPSIIIC mice have a hyperactive phenotype in the 1 h
open ﬁeld test (Martins et al., 2015) (Fig. 6D). The hyper-
active phenotype, assessed by total distance moved was
Figure 5 AAV-TToutperforms AAV9 and AAVrh10 in GFP biodistribution studies. GFP vectors were packaged into AAV9, AAVrh10 or
AAV-TT capsids and used for comparative biodistribution studies. (A–C) Representative confocal microscopy images showing GFP expression in the
CNS of mice 3 weeks after they were injected with the three different marker viruses. The white squares indicate the areas that are shown at higher
magnification in D. (D) Representative confocal images showing GFP expression in the areas indicated in (A–C). Scale bar = 50mm. (E) NeuN
staining of brain sections of adult mice treated with AAV-TT shows that AAV-TT specifically transduces neurons. Scale bar = 20mm. The percentage
of NeuN/GFP co-localizing cells in the (F) thalamus (G) amygdala and (H) somatosensory cortex in AAV9- and AAV-TT-treated mice.
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corrected in AAV-TT treated MPSIIIC mice at 4 months
post-treatment, but not in AAV9-treated mice [effect of
treatment, F(3,30) = 7.68, P5 0.001] (Fig. 6D). Impaired
cognitive abilities in MPSIIIC mice can be evaluated by
assessing working memory as determined by the number
of correct entries into the different arms of a Y-maze
(Hughes, 2004) (Fig. 6E). This spontaneous alternation
task takes advantage of the natural tendency for the
mouse to explore novel environments; measurement of
working memory in this task consists of an increase in ex-
ploration of a novel arm compared to a recently explored
arm of the maze (Deacon et al., 2002). Consistent with
correction of hyperactivity, AAV-TT treated mice showed
signiﬁcant improvements in immediate spatial working
memory and correction to wild-type levels in the Y-maze
[effect of treatment, F(3,35) = 3.806, P 5 0.05] (Fig. 6F).
AAV9 had a more variable effect that was not signiﬁcantly
improved over MPSIIIC sham.
No statistically signiﬁcant differences in vector copy num-
bers in the brain were found among the groups with aver-
age numbers of 39.15  16.91 and 45.09  16.29 for
AAV9 and AAV-TT, respectively (Fig. 6G). Little to no
off-target transduction of AAV9 and AAV-TT to peripheral
organs was observed in treated mice with vg/cell values
generally under 0.5 vg/cell (Supplementary Fig. 6A, C, E
and G). Consistent with vector genome results, no
HGSNAT enzyme was detected in spleen, lung and
kidney, in all treated animals (Supplementary Fig. 6B, D,
F and H).
AAV-TT further improves
brain-specific HGSNAT activity at 6
months in MPSIIIC mice
At 6 months post-treatment, AAV-TT and AAV9 vectors
expressing coHGSNAT increased overall brain enzyme ac-
tivity levels to above wild-type levels [effect of treatment,
F(3,97) = 14.19, P5 0.0001]; but higher levels were ob-
tained in AAV-TT (266.5%) treated mice compared to
AAV9-treated mice (185.2%) (Fig. 6H). The brain was
divided into hemicoronal ﬁfths (anterior to posterior
R1–R5; Fig. 6B), with enzyme activity detected throughout
the brain but highest around the injection site in R2 [effect
of treatment  brain region, F(12,97) = 4.91, P5 0.0001]
(Fig. 6I). In contrast to earlier observations at 1 week
and 3 weeks post-treatment (Supplementary Fig. 5C and
D), enzyme levels mediated by AAV-TT at 6 months
post-treatment were signiﬁcantly greater than AAV9
Figure 6 AAV-TTeffectively corrects disease phenotype in MPSIIIC mice. (A) AAV-HGSNAT vectors, packaged into AAV9 or
AAV-TT capsids, were used to treat MPSIIIC mice. (B) Schematic of injection site and brain sectioning used for enzyme level determination.
(C) Overview of treatment and analysis scheme. (D) Hyperactivity as measured by distance travelled by wild-type (wt, n = 8) and MPSIIIC sham
(n = 11), AAV9 (n = 8) and AAV-TT (n = 7) treated MPSIIIC mice. (E) Configuration of Y-maze. (F) Cognitive ability as measured by the
percentage of alternation in the Y- maze of wild-type (n = 10) and MPSIIIC sham (n = 12), AAV9 (n = 9) and AAV-TT (n = 9) treated MPSIIIC mice.
(G) Vector genome copy numbers (vg/cell) measured by qPCR in whole brain tissue preparations from wild-type (n = 1), MPSIIIC (n = 1), AAV9
(n = 6) and AAV-TT (n = 6) treated MPSIIIC mice. (H) HGSNAT enzyme activity measured in whole brain preparations of wild-type (n = 6),
MPSIIIC (n = 6), AAV9 (n = 6) and AAV-TT (n = 6) treated MPSIIIC mice. (I) HGSNAT enzyme activity measured in brain sections R1–R5.
(J) Total IgG antibody responses against AAV9 capsid proteins as measured by ELISA. Absence of capsid-specific antibodies in brain homogenates
of AAV9-coHGSNAT (n = 6) treated mice. (K) Total IgG antibody responses against AAV-TT capsid proteins as measured by ELISA. Absence of
capsid-specific antibodies in brain homogenates of AAV-TT-HGSNAT (n = 6) treated mice. Positive controls consist of mice treated with vectors
and adjuvant. ANOVA followed by Tukey’s post hoc multiple comparison test. Data are presented as mean  SEM; *P5 0.05; **P5 0.01;
***P5 0.001; ****P5 0.0001.
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Figure 7 AAV-TTreduces primary and secondary storage molecules leading to a reduction in neuroinflammation in MPSIIIC
mice. (A) Primary storage i.e. total HS measured by reversed phase chromatography in brains in wild-type (wt, n = 6), untreated MPSIIIC (n = 6),
AAV9 (n = 6) and AAV-TT (n = 6) treated MPSIIIC mice. (B) Measurement of the different disaccharide contributions in HS in wild-type (n = 6),
untreated MPSIIIC (n = 6), AAV9 (n = 6) and AAV-TT (n = 6) treated MPSIIIC mice shows normalization of the relative proportion of HS that is
NAc, 6S and 2S sulphated. (C) Secondary storage i.e. GM3 gangliosides measured by thin layer chromatography in homogenized brain tissues of
wild-type (n = 4), untreated MPSIIIC (n = 3), AAV9 (n = 4) and AAV-TT (n = 4) treated MPSIIIC mice, which is reduced in treated MPSIIIC mice.
(D) Storage of GM2 ganglioside in the hippocampus of wild-type (n = 2), untreated MPSIIIC (n = 6), AAV9 (n = 3) and AAV-TT (n = 4) treated
MPSIIIC mice, which is reduced in treated MPSIIIC mice. (E and F) Storage of GM3 stained brain sections in the M2 cortex of wild-type (n = 2),
untreated MPSIIIC (n = 6), AAV9 (n = 3) and AAV-TT (n = 4), which is reduced in treated MPSIIIC mice. Scale bar = 20mm. (G and H) Confocal
microscopy of GFAP stained brain sections in wild-type (n = 4), untreated MPSIIIC (n = 3), AAV9 (n = 4) and AAV-TT (n = 4) treated MPSIIIC mice
shows trend towards reduction in the accumulation of GFAP positive astrocytes in the thalamus of treated MPSIIIC mice. (I and J) Confocal
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(P50.001) in R2 at 767.78% and 453.03%, respectively
(Fig. 6I). Despite supra-physiological enzyme levels in trea-
ted brains, both AAV9 (Fig. 6J) and AAV-TT (Fig. 6K)
capsids produced no detectable levels of anti-AAV IgG anti-
bodies in the brains of all treated mice, in contrast to posi-
tive control mice that received a mixture of adjuvant and
either AAV9 or AAV-TT to stimulate signiﬁcant IgG
responses.
AAV-TT and AAV9 reduce primary
storage of heparan sulphate, while
AAV-TT improves heparan sulphate
patterning in vivo
MPSIIIC mice display a 13.4-fold increase in primary storage
of HS in the brain compared to wild-type (Fig. 7A). Overall,
AAV9 and AAV-TT both reduced total HS levels by 46%
[effect of treatment, F(3,20) = 10.03, P5 0.001].
Abnormal highly sulphated UA(2S)-GlcNS(6S) (P5 0.0001)
and UA(2S)-GlcNS (P5 0.0001) HS species were seen in the
brains of MPSIIIC mice; with a reduction in the un-sulphated
UA-N-acetyl-glucosamine (GlcNAc) (P5 0.0001) groups.
AAV-TT reduced UA(2S)-GlcNS(6S) residues compared to
MPSIIIC (P5 0.01), whereas levels in AAV9 treated mice re-
mained unchanged. AAV-TT was signiﬁcantly better at cor-
recting abnormal UA(2S)-GlcNS (P5 0.01) and UA-GlcNAc
(P50.0001) disaccharide composition than AAV9 (Fig. 7B).
AAV-TT and AAV9 reduce secondary
storage of GM2 and GM3 gangliosides
in the brain of MPSIIIC mice
It has been previously reported that both GM3 and GM2
gangliosides are signiﬁcantly increased in the brains of
MPSIIIC mice (Martins et al., 2015).
GM3 storage is observed (in the order of storage level) in
the hypothalamus, amygdala, midbrain, medial entorhinal
cortex (MEnt), secondary motor cortex (M2), secondary
visual cortex mediolateral, and hippocampus including the
molecular layer of the dentate gyrus. AAV treatment with
both serotypes signiﬁcantly reduced overall levels of GM3
gangliosides in the brains of MPSIIIC mice at 6 months
post-injection (P5 0.01) (Fig. 7C) including the secondary
motor cortex (M2) (Fig. 7E and F) and the medial entorh-
inal cortex (Supplementary Fig. 7B).
GM2 ganglioside levels are abnormally elevated through-
out the MPSIIIC brain but particularly (in the order of
storage level) in the amygdala, pons, medulla, midbrain,
hypothalamus, reticular nucleus of the thalamus, medial
entorhinal cortex, cortex, hippocampus and cerebellum.
These were reduced in the hippocampus in both groups
of treated mice compared to untreated mice (Fig. 7D)
and appear reduced in other brain areas (Supplementary
Fig. 7C).
AAV-TT and AAV9 reduce
astrocytosis and lysosomal burden
in the brain of MPSIIIC mice
Astrocytosis was observed in the thalamus of MPSIIIC mice
with non-signiﬁcant reductions of GFAP (Fig. 7G and H) in
both AAV9 and AAV-TT treated groups; no differences
were observed in GFAP-positive astrocytes between
MPSIIIC and both treated groups in the external capsule
(Supplementary Fig. 8A), caudate putamen (Supplementary
Fig. 8B), amygdala (Supplementary Fig. 8C) and the cortex
(Supplementary Fig. 8D). Levels of LAMP2 lysosomal stor-
age were signiﬁcantly decreased by both vectors (P5 0.01)
in the caudate putamen, an area close to the injection site [ef-
fect of treatment, F(3,11) = 16.52, P5 0.001] (Fig. 7I and J).
A similar trend was observed in areas distant from the in-
jection site including the external capsule (Supplementary
Fig. 9A) and cortex (Supplementary Fig. 9D) and less so
in the thalamus (Supplementary Fig. 9B) and amygdala
(Supplementary Fig. 9C).
AAV-TT corrects neuroinflammation
over AAV9 in the caudate putamen
and amygdala of MPSIIIC mice
Immunohistochemical analysis of the brain showed a better
correction of inﬂammation in terms of the number of iso-
lectin B4-positive microglial cells in AAV-TT than AAV9
treated (P50.05) mice in the caudate putamen [effect of
treatment, F(3,12) = 88.27, P5 0.0001] (Fig. 7K and L)
and in the amygdala [effect of treatment, F(3,12) = 264,
P5 0.0001] (Supplementary Fig. 10C). AAV-TT reduced
inﬂammation (P 5 0.001) similarly to AAV9 (P 5 0.05)
in the cortex [effect of treatment, F(3,12) = 92.8,
P5 0.0001] (Supplementary Fig. 10D); with no improve-
ments in the hippocampus (Supplementary Fig. 10A), thal-
amus (Supplementary Fig. 10B) and amygdala
(Supplementary Fig. 10C).
Figure 7 Continued
microscopy of LAMP2 stained brain sections in wild-type (n = 4), untreated MPSIIIC (n = 3), AAV9 (n = 4) and AAV-TT (n = 4) treated MPSIIIC
mice shows reduction in lysosomal LAMP2 staining in the caudate putamen in treated MPSIIIC mice. (K and L) Confocal microscopy of ILB4
stained brain sections in wild-type (n = 4), untreated MPSIIIC (n = 4), AAV9 (n = 4) and AAV-TT (n = 4) treated MPSIIIC mice shows improvement
in neuroinflammation in the caudate putamen in AAV-TT-HGSNAT treated mice. ANOVA followed by Tukey’s post hoc multiple comparison test.
Data are mean  SEM; *P5 0.05; **P5 0.01; ***P5 0.001; ****P5 0.0001. Scale bar = 50mm.
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Discussion
We used an alternative capsid design approach to generate a
variant of AAV2, which is closely related to natural variants
that presumably have evolved to efﬁciently infect human
tissues. Intriguingly, when injected in rodents, vectors
based on this new capsid show strong tropism for the
CNS, including photoreceptors in the eye, rather than for
peripheral organ systems, which may be due to changes in
the receptor footprint (Asokan et al., 2010; Drouin and
Agbandje-McKenna, 2013). One of the most notable
changes is the abolished HSPG binding site (Wu et al.,
2000; Grifman et al., 2001; Kern et al., 2003; Opie et al.,
2003), which steers the AAV-TT capsid away from its tissue
culture adapted tropism features and contributes to an
increased spread in the CNS in vivo. In general, it is thought
that high expression levels of HSPG on cell surfaces and
extracellular matrix leads to reduced spread and sequestra-
tion of AAV2 in ‘off target’ tissues (Perabo et al., 2006). In
the CNS particularly, it has been shown that high afﬁnity
for HSPG is detrimental for the spread of transduction by
AAV2 (Mastakov et al., 2002; Kanaan et al., 2017).
However, preliminary experiments indicate that mutation
of the HSPG binding site in AAV2 (R585S and R588S)
increases transduction spread and efﬁciency compared to
wild-type AAV2 but to a lower extent than observed for
AAV-TT, arguing that additional amino acid changes con-
tribute to the observed phenotype (data not shown). The
combined effect of all amino acid replacements is likely to
contribute to the increased thermal stability observed for
AAV-TT as the difference in stability between AAV-TT
and AAV2 is larger than the previously described increase
in an AAV2-HSPG null variant, which harbours mutations
at positions 585 and 588 (Pacouret et al., 2017). However,
the mechanistic link between enhanced capsid stability and
increased transduction ability is not entirely understood; pri-
mary differences between the capsid variants in various as-
pects of vector biology, ranging from uptake to genome
release in the nucleus, could potentially contribute to the
observed differences in transduction efﬁcacy.
Given the encouraging results achieved in AAV2/AAV-
TT comparative biodistribution studies, we assessed the ef-
ﬁcacy of AAV-TT in correcting neurological deﬁcits in the
mouse model of MPSIIIC by comparing it to preferred
neurological serotypes. Preparatory GFP distribution stu-
dies suggested that at the indicated dose, AAV9 yields
very high transduction of cells in localized areas and is
not well distributed. In contrast, AAV-TT has less intense
levels of staining with a larger proportion of neurons
throughout the brain transduced. In adult rodents, neurons
are the major cell type transduced with all vectors within
both the white and grey matter (Herculano-Houzel, 2014),
in keeping with data from AAV9 and AAVrh10 (Cearley
and Wolfe, 2006).
It should be noted that AAV-TT and AAVrh10 were af-
ﬁnity-puriﬁed and therefore contained a higher number of
empty capsids compared to AAV9, which was puriﬁed
using density gradient centrifugation. The previously
described role for empty capsids as decoy for AAV-speciﬁc
antibodies is unlikely to play a role in the brain given the
fact that we could not even detect AAV-speciﬁc antibodies
after treatment (Mingozzi et al., 2013). However, empty
capsids could potentially compete for receptor binding
and uptake thereby putting AAV-TT and AAVrh10 at a
disadvantage compared to AAV9. Nevertheless, our results
show that AAV-TT performed better than AAV9 in the
biodistribution studies and was more efﬁcient in correcting
the disease in MPSIIIC mice.
Both short-term and long-term data from MPSIIIC mice
showed supra-physiological enzyme levels in areas close to
the injection site, a distribution pattern seen in other pre-
clinical studies using AAV vectors to treat MPSIIIA
(Winner et al., 2016) or MPSIIIB (Fu et al., 2002).
Importantly, the treatment did not elicit an antibody re-
sponse in the brains of MPSIIIC mice.
Although the neuropathology of the brain was corrected
in only some regions, we were able to achieve correction of
hyperactive behaviour and working memory in AAV-TT
treated mice over AAV9 treated mice. It is unclear which
brain area is responsible for hyperactivity in MPS, how-
ever, the frontostriatal pathway has been implicated in
ADHD (Cubillo et al., 2012), as it is involved in control
of impulsivity, locomotion, affect, attention and emotion
(Takamatsu et al., 2015). This pathway connects the
cortex, striatum and thalamus (Morris et al., 2016), areas
in which we have observed improvement in LAMP2, GFAP
and ILB4 levels with AAV-TT treatment. Hyperactivity
could also be a circadian effect controlled from the supra-
chiasmiatic nucleus as we have hypothesized earlier (Canal
et al., 2010), or from areas projecting from the suprachias-
miatic nucleus such as the thalamus (Schwartz et al., 2011).
The Y-maze is a widely used test measuring working
memory and has been used to study hippocampal function
as performance of rodents in this test is disrupted by hip-
pocampal lesions (Rawlins and Olton, 1982; Hock and
Bunsey, 1998). The results obtained from the Y-maze test
correlate with GFP expression data showing hippocampal
vector expression and suggest that effectively transducing
these areas can restore hippocampal based learning.
HS has been implicated for its role in neuroinﬂammation
(Zhang et al., 2014), interestingly, AAV-TT treatment im-
proved both HS sulphation patterning and neuroinﬂamma-
tion over AAV9 in several areas. We hypothesize that the
sulphation patterning of HS may contribute to neuroin-
ﬂammation in MPSIIIC potentially resulting in subsequent
behavioural abnormalities. These data are consistent with
previous ﬁndings that suggest that restoring sulphation pat-
terning of HS and reducing inﬂammation may be key in
improving behavioural outcomes in MPSIII (Sergijenko
et al., 2013).
GM2 and GM3 gangliosides have a still undeﬁned role in
MPSIIIC neuropathology, and respond differentially to
AAV treatment. It has been previously reported that GM2
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and GM3 gangliosides showed only modest levels of co-lo-
calization by both region and subcellular compartment in
the brains of MPSIII mice (McGlynn et al., 2004; Martins
et al., 2015) with storage also observed in the medial
entorhinal cortex in MPSIIIB mice (Ryazantsev et al.,
2007; Ohmi et al., 2011). This suggests that different
pathological mechanisms underlie storage of GM2 and
GM3 gangliosides in MPSIIIC potentially explaining why
they respond differently to restoration of the primary
HGSNAT deﬁciency by AAV-mediated gene correction.
In a disease with global pathology such as MPSIIIC
where the enzyme is not secreted and thus cannot cross-
correct other cells, maximum cell transduction is required.
A similar AAV-based approach has been developed in the
non-cross correctable neurological disease CLN3, resulting
in some disease correction, although neonatal delivery of
AAV is often much more effective than delivery to adult
mice (Sondhi et al., 2014). Notably an intravenous AAV9
approach in CLN3 was only partly effective, underlining
the difﬁculty of treating non-cross correctable neurological
diseases (Bosch et al., 2016).
Our data for the ﬁrst time show that the neurological
non cross-correctable lysosomal disease MPSIIIC can be
treated via AAV-mediated gene therapy suggesting that
this may be a therapeutic option for patients.
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